These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12555016)

  • 1. New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines.
    Demols A; Deviere J
    JOP; 2003 Jan; 4(1):49-57. PubMed ID: 12555016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing post-ERCP pancreatitis: where are we?
    Testoni PA
    JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk.
    Sherman S; Cheng CL; Costamagna G; Binmoeller KF; Puespoek A; Aithal GP; Kozarek RA; Chen YK; Van Steenbergen W; Tenner S; Freeman M; Monroe P; Geffner M; Deviere J;
    Pancreas; 2009 Apr; 38(3):267-74. PubMed ID: 19214137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis.
    Madácsy L; Kurucsai G; Fejes R; Székely A; Székely I
    Dig Endosc; 2009 Jan; 21(1):8-13. PubMed ID: 19691794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of post-ERCP pancreatitis directly proportional to the invasiveness of endoscopic intervention: a pilot study in a canine model.
    Buscaglia JM; Simons BW; Prosser BJ; Ruben DS; Giday SA; Magno P; Clarke JO; Shin EJ; Kalloo AN; Kantsevoy SV; Gabrielson KL; Jagannath SB
    Endoscopy; 2008 Jun; 40(6):506-12. PubMed ID: 18478511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
    Poon RT; Fan ST
    JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin injection after biliary sphincterotomy.
    Gorelick A; Barnett J; Chey W; Anderson M; Elta G
    Endoscopy; 2004 Feb; 36(2):170-3. PubMed ID: 14765315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indomethacin for post-ERCP pancreatitis prophylaxis: another attempt at the Holy Grail.
    Wagh MS; Sherman S
    Am J Gastroenterol; 2007 May; 102(5):984-6. PubMed ID: 17489783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Freeman ML
    Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1354-65. PubMed ID: 17981248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis.
    Elmunzer BJ; Waljee AK; Elta GH; Taylor JR; Fehmi SM; Higgins PD
    Gut; 2008 Sep; 57(9):1262-7. PubMed ID: 18375470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
    Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
    BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
    Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
    JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis.
    Hackert T; Werner J; Gebhard MM; Klar E
    Surgery; 2004 Feb; 135(2):131-8. PubMed ID: 14739847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
    Budzyńska A; Marek T; Nowak A; Kaczor R; Nowakowska-Dulawa E
    Endoscopy; 2001 Sep; 33(9):766-72. PubMed ID: 11558030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications.
    Tarnasky PR
    JOP; 2003 Jan; 4(1):58-67. PubMed ID: 12555017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-ERCP pancreatitis and its prevention.
    Frank CD; Adler DG
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):680-8. PubMed ID: 17130878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis.
    Masci E; Mariani A; Curioni S; Testoni PA
    Endoscopy; 2003 Oct; 35(10):830-4. PubMed ID: 14551860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept, a TNF-alpha binding agent, is ineffective in the prevention of post-ERCP pancreatitis in canines.
    Buscaglia JM; Simons BW; Prosser BJ; Ruben DS; Giday SA; Magno P; Clarke JO; Shin EJ; Kalloo AN; Kantsevoy SV; Gabrielson KL; Jagannath SB
    JOP; 2008 Jul; 9(4):456-67. PubMed ID: 18648137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.